These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 32296414)

  • 21. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
    da Costa L; Renner C; Hartmann F; Pfreundschuh M
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential application and prevalence of the CD30 (Ki-1) antigen among solid tumors: A focus review of the literature.
    Berger GK; Gee K; Votruba C; McBride A; Anwer F
    Crit Rev Oncol Hematol; 2017 May; 113():8-17. PubMed ID: 28427526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hodgkin lymphoma].
    Nishikori M
    Rinsho Ketsueki; 2019; 60(5):447-452. PubMed ID: 31168012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of CD30, CD40 and CD95 in the regulation of proliferation and apoptosis in classical Hodgkin's lymphoma.
    Kim LH; Eow GI; Peh SC; Poppema S
    Pathology; 2003 Oct; 35(5):428-35. PubMed ID: 14555388
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precursor cells and implications of a T-cell inflamed immune response in the pre-malignant setting in Hodgkin lymphoma.
    Hollander P; Ginman B; Molin D; Enblad G; Amini RM; Glimelius I
    Immunobiology; 2020 Jan; 225(1):151872. PubMed ID: 31787352
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.
    Wang Y; Nowakowski GS; Wang ML; Ansell SM
    J Hematol Oncol; 2018 Apr; 11(1):57. PubMed ID: 29685160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD30 ligand expression in nonmalignant and Hodgkin's disease-involved lymphoid tissues.
    Gruss HJ; Pinto A; Gloghini A; Wehnes E; Wright B; Boiani N; Aldinucci D; Gattei V; Zagonel V; Smith CA; Kadin ME; von Schilling C; Goodwin RG; Herrmann F; Carbone A
    Am J Pathol; 1996 Aug; 149(2):469-81. PubMed ID: 8701986
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated Serum Levels of sCD30 and IL6 and Detectable IL10 Precede Classical Hodgkin Lymphoma Diagnosis.
    Levin LI; Breen EC; Birmann BM; Batista JL; Magpantay LI; Li Y; Ambinder RF; Mueller NE; Martínez-Maza O
    Cancer Epidemiol Biomarkers Prev; 2017 Jul; 26(7):1114-1123. PubMed ID: 28341757
    [No Abstract]   [Full Text] [Related]  

  • 29. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
    Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
    Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
    Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
    Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Editorial: ADAM10 in Cancer Immunology and Autoimmunity: More Than a Simple Biochemical Scissor.
    Rossello A; Steinle A; Poggi A; Zocchi MR
    Front Immunol; 2020; 11():1483. PubMed ID: 32765514
    [No Abstract]   [Full Text] [Related]  

  • 32. CD30, Th2 cytokines and HIV infection: a complex and fascinating link.
    Del Prete G; Maggi E; Pizzolo G; Romagnani S
    Immunol Today; 1995 Feb; 16(2):76-80. PubMed ID: 7888070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sequential development of Hodgkin's disease and CD30+ diffuse large B-cell lymphoma in a patient with MALT-type lymphoma: evidence of different clonal origin of single microdissected Reed-Sternberg cells.
    Parrens M; Vergier B; Fitoussi O; Lahet C; Belleannee G; Marit G; Dubus P; de Mascarel A; Delfau-Larue MH; Merlio JP
    Am J Surg Pathol; 2002 Dec; 26(12):1634-42. PubMed ID: 12459631
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma.
    Scott LJ
    Drugs; 2017 Mar; 77(4):435-445. PubMed ID: 28190142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunohistochemistry of Hodgkin and non-Hodgkin lymphomas with emphasis on the diagnostic significance of the BNH9 antibody reactivity with anaplastic large cell (CD30 positive) lymphomas.
    Carbone A; Gloghini A; Volpe R
    Cancer; 1992 Dec; 70(11):2691-8. PubMed ID: 1330287
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Brentuximab Vedotin in Relapsed or Refractory High-CD30-Expressing Non-Hodgkin Lymphomas: Results of a Multicenter, Open-Labeled Phase II Trial.
    Kim SJ; Yoon DH; Kim JS; Kang HJ; Lee HW; Eom HS; Hong JY; Cho J; Ko YH; Huh J; Yang WI; Park WS; Lee SS; Suh C; Kim WS
    Cancer Res Treat; 2020 Apr; 52(2):374-387. PubMed ID: 31476851
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma.
    Alperovich A; Younes A
    Cancer J; 2016; 22(1):23-6. PubMed ID: 26841013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ki-4(scFv)-ETA', a new recombinant anti-CD30 immunotoxin with highly specific cytotoxic activity against disseminated Hodgkin tumors in SCID mice.
    Barth S; Huhn M; Matthey B; Tawadros S; Schnell R; Schinköthe T; Diehl V; Engert A
    Blood; 2000 Jun; 95(12):3909-14. PubMed ID: 10845927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.
    Francisco JA; Cerveny CG; Meyer DL; Mixan BJ; Klussman K; Chace DF; Rejniak SX; Gordon KA; DeBlanc R; Toki BE; Law CL; Doronina SO; Siegall CB; Senter PD; Wahl AF
    Blood; 2003 Aug; 102(4):1458-65. PubMed ID: 12714494
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.